|
|
| Maladies Respiratoires > Etude de marché sectorielle |
| Monoclonal Antibodies in Asthma: The choice between life and breath? |
|
|
|
|
€ 1 615,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Février 2006 |
Taille du document : |
49 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (5) |
|
|
|
| 61 pages | Août 2004 | Anglais
|
|
|
| Main
focus: |
asthma,copd,cold remedy,pharmaceutical,...
|
| Research
focus: |
market size and estimates,demand analysis, |
| Geographic
focus: |
usa,united kingdom,belgium,spain,australia |
| |
|
|
|
|
| 62 pages | Août 2004 | Anglais
|
|
|
| Main
focus: |
asthma,copd,cold remedy,pharmaceutical,...
|
| Research
focus: |
market size and estimates,demand analysis, |
| Geographic
focus: |
usa,united kingdom,belgium,spain |
| |
|
|
|
|
| 50 pages | Juin 2006 | Anglais
|
|
|
| Main
focus: |
asthma,copd,magazines,newspaper
|
| Research
focus: |
market size and estimates,market definition, |
| Geographic
focus: |
usa,austria |
| |
|
|
|
|
| 50 pages | Novembre 2004 | Français
|
|
|
| Main
focus: |
maladie respiratoire,fruit,fruits
|
| Research
focus: |
tendances et évolution du marché, |
| Geographic
focus: |
france,chine,inde,usa,madagascar,japon,réunion,... |
| |
|
|
|
|
| 43 pages | Juillet 2005 | Anglais
|
|
|
| Main
focus: |
asthma,respiratory disease,hospital,emergency,...
|
| Research
focus: |
economy outlook,market segmentation,market outlook, |
| Geographic
focus: |
australia,usa,netherlands |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Partneringreview 2006 – Therapy area (volume 2)
1802 pages | Février 2006 |
Partneringreview 2006 – Volume 2: Therapy area provides an in depth view into the deals and alliances by therapeutic area announced in 2005, in a clear and accessible format.
The report reviews ove |
2 295,00 €
|
| |
| |
US State Market Index: Antihistamine preparations
12 pages | Juillet 2006 |
The metrics in this report cover three year trends in Antihistamine preparations [Manufacturing sector], broken out on a state-by-state basis.
Analysis is based on data applied from 2 industry firm |
475,00 €
|
| |
| |
Travel and Tourism - Poland
34 pages | Août 2006 |
About this reportSince its break with communism in 1989 and its first democratic election Poland has become an increasingly popular destination choice for foreign tourists.
This diverse country boa |
445,00 €
|
| |
| |
Sustainable Tourism in the Travel Industry International
77 pages | Février 2005 |
About this reportAbout the market… “Just as SARS (Severe Acute Respiratory Syndrome) and 9/11 caused widespread disruption to the tourism industry, so the tsunami in the Indian Ocean in December 2004 |
445,00 €
|
| |
| |
US Cough Syrup 2005
13 pages | Juin 2005 |
Snapdata's US Cough Syrup 2005 report provides 2004 year-end market data, with 2005 estimates and five-year forecasts.
The report gives an instant overview of the US cough syrup market, and covers |
240,00 €
|
| |
| |
Commercial Insight: Herpes and Respiratory Antivirals - Leaders Rise and Fall
218 pages | Octobre 2005 |
IntroductionWithin the herpes and respiratory antiviral subcategory HSV/VZV products have been key growth drivers, accounting for 77% of a market worth $2,190m in 2004.
Despite lost of US branded V |
9 690,00 €
|
| |
| |
Activity Holidays
154 pages | Février 2006 |
This Market Assessment report covers the market for activity holidays, which are defined to include a wide variety of events that involve some form of physical exertion, ranging from rambling and fish |
1 260,00 €
|
| |
| |
OTC Cough and Cold Remedies in Germany
10 pages | Juin 2005 |
Euromonitor International’s ‘OTC Cough and Cold Remedies in Germany' Major Market Profile report offers an introduction to the market.
It is c.
10 pages long and provides a top line overview of |
198,00 €
|
| |
| |
Respiratory Drugs
318 pages | Juillet 2006 |
This report analyzes the worldwide markets for Respiratory Drugs in US$ Million.
The major product segments analyzed are Asthma, Allergic Rhinitis, and COPD (Chronic Obstructive Pulmonary Disease). |
3 160,00 €
|
| |
| |
US State Market Index: Drugs acting on the respiratory system
12 pages | Juillet 2006 |
The metrics in this report cover three year trends in Drugs acting on the respiratory system [Manufacturing sector], broken out on a state-by-state basis.
Analysis is based on data applied from 29 |
475,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Monoclonal Antibodies in Asthma: The choice between life and breath? |
|
|
Introduction
Although only 5% of asthma suffers have severe asthma, these patients account for a disproportionately high percentage of healthcare spending, as asthma-related hospitalizations and emergency room visits are two of the costliest outcomes, which highlights the significant unmet need in this market.
Scope
Evaluation of the market potential and dynamics of Xolair, currently the only marketed respiratory monoclonal antibody
Examination of the key mediators in asthma and the evidence supporting their role
Identification and evaluation of fifteen monoclonal antibodies currently in preclinical or clinical development to treat asthma
Assessment of drivers and resistors of using monoclonal antibodies in the severe asthma market
Highlights
Xolair is set to dominate the respiratory monoclonal antibody market through to 2010, and data from the TENOR study may help Genentech and Novartis to further increase market penetration if a role for IgE in non-atopic asthma is identified.
Th2 mediators are the target of most respiratory monoclonal antibody programs, of which IL-13 is generating the greatest interest, with one third of programs targeting this mediator.
Although there is a significant unmet need among severe asthma patients who are non-responsive to corticosteroids, the price point of respiratory monoclonal antibodies will limit penetration in cost-conscious Europe, transforming the US into the dominant revenue-creation market.
Reasons to Purchase
Evaluate the current state of the monoclonal antibodies market and the market capture potential for these products in severe asthma
Assess the key technological trends to capitalize on opportunities in the respiratory monoclonal antibody sector
Identify possible targets to focus monoclonal antibody design
|
|
Introduction
Although only 5% of asthma suffers have severe asthma, these patients account for a disproportionately high percentage of healthcare spending, as asthma-related hospitalizations and emergency room visits are two of the costliest outcomes, which highlights the significant unmet need in this market.
Scope
Evaluation of the market potential and dynamics of Xolair, currently the only marketed respiratory monoclonal antibody
Examination of the key mediators in asthma and the evidence supporting their role
Identification and evaluation of fifteen monoclonal antibodies currently in preclinical or clinical development to treat asthma
Assessment of drivers and resistors of using monoclonal antibodies in the severe asthma market
Highlights
Xolair is set to dominate the respiratory monoclonal antibody market through to 2010, and data from the TENOR study may help Genentech and Novartis to further increase market penetration if a role for IgE in non-atopic asthma is identified.
Th2 mediators are the target of most respiratory monoclonal antibody programs, of which IL-13 is generating the greatest interest, with one third of programs targeting this mediator.
Although there is a significant unmet need among severe asthma patients who are non-responsive to corticosteroids, the price point of respiratory monoclonal antibodies will limit penetration in cost-conscious Europe, transforming the US into the dominant revenue-creation market.
Reasons to Purchase
Evaluate the current state of the monoclonal antibodies market and the market capture potential for these products in severe asthma
Assess the key technological trends to capitalize on opportunities in the respiratory monoclonal antibody sector
Identify possible targets to focus monoclonal antibody design
|
|
|
PPLSEN
|
|
|
|
|
